Oshima et al. 34analyzed the Food and Drug Administration Adverse Event Reporting System database and investigated the association between pneumonitis and the combination of nivolumab and EGFR‐tyrosine kinase inhibitor (TKI). This evidence concerns the gene EGFR and pneumonitis.